BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) General Counsel Vincent Paul Liptak purchased 2,500 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was bought at an average cost of $15.80 per share, with a total value of $39,500.00. Following the purchase, the general counsel owned 109,212 shares of the company’s stock, valued at approximately $1,725,549.60. This trade represents a 2.34% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Vincent Paul Liptak also recently made the following trade(s):
- On Monday, August 10th, Vincent Paul Liptak acquired 2,200 shares of BlossomHill Therapeutics stock. The shares were bought at an average price of $16.00 per share, with a total value of $35,200.00.
BlossomHill Therapeutics Stock Down 0.1%
BlossomHill Therapeutics stock opened at $15.99 on Tuesday. BlossomHill Therapeutics, Inc. has a one year low of $15.25 and a one year high of $17.25.
See Also
- Five stocks we like better than BlossomHill Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
